Vericel prelim FY2022 rev ~$164-165M; MACI arthro launch accelerated to 2024; NexoBrid approved

Vericel Corp

Full-year 2022 total revenue expected ~$164-165M; MACI rev ~$132M at high end of guidance.
Q4 MACI revenue growth ~24% YoY; 10th straight quarter of positive adjusted EBITDA and operating cash flow.
Cash and investments ~$140M, no debt as of Dec 31, 2022.
NexoBrid FDA approved Dec 28, 2022 for eschar removal in thermal burns; U.S. commercial launch expected Q2 2023.
MACI arthroscopic delivery human factors study planned for 2023; commercial launch now expected in 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vericel Corp reported the year ended December 31, 2022 results: revenue approximately $164 to $165 million.

Period: the year ended December 31, 2022
Revenue: approximately $164 to $165 million
Result: preliminary results

Exact text from the filing

Total net revenue for full-year 2022 expected to be approximately $164 to $165 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vericel Corp reported preliminary financial results for the fourth quarter ended December 31, 2022.

Period: the fourth quarter ended December 31, 2022
Result: preliminary results

Exact text from the filing

Fourth quarter MACI revenue growth expected to be approximately 24% versus prior year

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Vericel Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-002721

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.